FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2439-2441 June 9, 2005 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Petersen, R. C. PubMed Citation

In this issue of the Journal, Petersen et al. present the long-awaited results of a randomized, placebo-controlled trial of donepezil, a standard therapy for Alzheimer's disease, and the widely used antioxidant vitamin E as an early intervention for mild cognitive impairment — essentially the prodromal phase of Alzheimer's disease.¹ The implications of this study for primary care medicine and for public health are enormous. The clear-cut negative findings for vitamin E, which is widely used despite the dearth of evidence of its efficacy, are especially noteworthy. The findings for donepezil, on the other hand, are much less clear.

Mild cognitive . . . [Full Text of this Article]

Source Information

From the Gerontology Research Unit, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, and the Department of Epidemiology, Harvard School of Public Health — all in Boston.

This article was published at www.nejm.org on April 13, 2005.

This article has been cited by other articles:

• Winblad, B., Gauthier, S., Scinto, L., Feldman, H., Wilcock, G. K., Truyen, L., Mayorga, A. J., Wang, D., Brashear, H. R., Nye, J. S., The GAL-INT-11/18 Study Group, (2008). Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 70: 2024-2035 [Abstract] [Full Text]  
• Chertkow, H. MD, Massoud, F. MD, Nasreddine, Z. MD, Belleville, S. PhD, Joanette, Y. PhD, Bocti, C. MD, Drolet, V. BSc, Kirk, J. MD, Freedman, M. MD, Bergman, H. MD (2008). Diagnosis and treatment of dementia: 3. Mild cognitive impairment and cognitive impairment without dementia. CMAJ 178: 1273-1285 [Abstract] [Full Text]  
• Perneczky, R., Pohl, C., Sorg, C., Hartmann, J., Komossa, K., Alexopoulos, P., Wagenpfeil, S., Kurz, A. (2006). Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues. Age Ageing 35: 240-245 [Abstract] [Full Text]  
• Jelic, V, Kivipelto, M, Winblad, B (2006). Clinical trials in mild cognitive impairment: lessons for the future. J. Neurol. Neurosurg. Psychiatry 77: 429-438 [Abstract] [Full Text]  
• Alagiakrishnan, K, McCracken, P, Feldman, H (2006). Treating vascular risk factors and maintaining vascular health: Is this the way towards successful cognitive ageing and preventing cognitive decline?. Postgrad. Med. J. 82: 101-105 [Abstract] [Full Text]  
• Navarro, A., Gomez, C., Sanchez-Pino, M.-J., Gonzalez, H., Bandez, M. J., Boveris, A. D., Boveris, A. (2005). Vitamin E at high doses improves survival, neurological performance, and brain mitochondrial function in aging male mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289: R1392-R1399 [Abstract] [Full Text]  
• (2005). Vitamin E and Donepezil in Patients with Mild Cognitive Impairment. JWatch General 2005: 3-3 [Full Text]